High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival

Oncology Letters
Daiyong WangQiaojia Huang

Abstract

Epidermal growth factor receptor (EGFR) is an essential regulator and biomarker of several types of cancer. However, the association between its expression and prognosis in patients with resected T3 stage gastric adenocarcinoma (RT3-GA) remains to be determined. In total, 683 patients with resectable T3-GA who underwent surgery were retrospectively included in the present study, and their immunohistochemical data for EGFR expression were collected. The associations between the patients' clinicopathologic characteristics and EGFR immunohistochemistry data were analyzed by multiple statistical methods. Annexin V apoptosis and MTT cell viability assays were performed to explore the effect of EGFR on AGS gastric adenocarcinoma cell survival. EGFR expression levels were categorized into two groups: low (406 cases) and high (277 cases). High EGFR was demonstrated to be significantly associated with distant metastasis (P=0.043) and severely decreased median overall survival time (MOST) and recurrence-free survival time (MRFST). MOST and MRFST in the low EGFR group were 39 and 37 months, respectively; whereas in the high EGFR group these values were only 18 and 13 months (P=3.10×10(-9) and P=6.74×10(-8), respectively). Multivariate ana...Continue Reading

References

Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M JackmanBruce E Johnson
Oct 13, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giovanni CorsoRaquel Seruca
Dec 4, 2013·Trends in Cell Biology·Alejandra TomasEmily R Eden
Feb 13, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kinisha Gala, Sarat Chandarlapaty
Apr 17, 2014·Journal of Cancer Research and Clinical Oncology·Xiaoting WangFeng Zheng
Feb 11, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Min-Hee RyuYoon-Koo Kang
Feb 24, 2015·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Alexandra Thiel, Ari Ristimäki
Mar 27, 2015·Translational Respiratory Medicine·Enric CarcerenyRafael Rosell
Oct 25, 2016·Trends in Pharmacological Sciences·E-E -Ke, Yi-Long Wu

❮ Previous
Next ❯

Citations

Mar 3, 2020·Frontiers in Genetics·Xiaohui SuWentao Wang
Oct 17, 2019·Micromachines·Jae Won ChoiDong Woo Lee
Apr 30, 2019·Journal of Cellular and Molecular Medicine·Pengxiang MinJun Du
Aug 27, 2019·Expert Review of Molecular Diagnostics·Rachel Sin-Yu ChoiSze Chuen Cesar Wong
May 26, 2021·Biochemical and Biophysical Research Communications·Na ChenYubin Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
electrophoresis
X-ray
flow cytometry

Software Mentioned

Quantity One
SPSS

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.